Apomorphine sublingual film - Sunovion Pharmaceuticals

Drug Profile

Apomorphine sublingual film - Sunovion Pharmaceuticals

Alternative Names: APL-130277; Apomorphine Hydrochloride Sublingual Thin Film

Latest Information Update: 20 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adagio Pharmaceuticals
  • Developer Sunovion Pharmaceuticals
  • Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Small molecules
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Parkinson's disease

Most Recent Events

  • 28 Jun 2018 Updated safety and efficacy data from a phase III pivotal study in Parkinson's disease release by Sunovion Pharmaceuticals
  • 12 Jun 2018 The US FDA sets PDUFA date of January 29, 2019 for NDA review for apomorphine sublingual film in Parkinson’s disease
  • 12 Jun 2018 US FDA accepts NDA for apomorphine sublingual film for Parkinson’s disease for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top